Publications in collaboration with researchers from Heidelberg University (21)

2022

  1. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease

    Molecular neurodegeneration, Vol. 17, Núm. 1, pp. 27

  2. Correction: Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease (Molecular Neurodegeneration, (2022), 17, 1, (27), 10.1186/s13024-022-00521-3)

    Molecular Neurodegeneration

  3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    JAMA Neurology, Vol. 79, Núm. 3, pp. 228-243

2021

  1. Csf proteomic alzheimer’s disease-predictive subtypes in cognitively intact amyloid negative individuals

    Proteomes, Vol. 9, Núm. 3

  2. Replication study of plasma proteins relating to Alzheimer's pathology

    Alzheimer's and Dementia, Vol. 17, Núm. 9, pp. 1452-1464

  3. Sex-specific metabolic pathways were associated with alzheimer’s disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

    Biomedicines, Vol. 9, Núm. 11

2020

  1. APOE ϵ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease

    Alzheimer's Research and Therapy, Vol. 12, Núm. 1

  2. Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology

    Journal of Alzheimer's Disease, Vol. 77, Núm. 3, pp. 1353-1368

  3. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort

    Journal of Alzheimer's Disease, Vol. 74, Núm. 1, pp. 213-225

2019

  1. A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort

    Alzheimer's and Dementia: Translational Research and Clinical Interventions, Vol. 5, pp. 933-938

  2. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum

    Alzheimer's and Dementia, Vol. 15, Núm. 5, pp. 644-654

  3. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay

    Alzheimer's and Dementia, Vol. 15, Núm. 11, pp. 1478-1488

  4. Inflammatory biomarkers in Alzheimer's disease plasma

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 776-787

  5. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

    Alzheimer's and Dementia, Vol. 15, Núm. 6, pp. 817-827

2016

  1. Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study

    Alzheimer's and Dementia, Vol. 12, Núm. 2, pp. 154-163

2015

  1. The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey

    Alzheimer's and Dementia, Vol. 11, Núm. 2, pp. 195-206.e1

2012

  1. Progression of Alzheimer disease in Europe: Data from the European ICTUS study

    Current Alzheimer Research, Vol. 9, Núm. 8, pp. 902-912

2010

  1. Assessing physician attitudes and perceptions of Alzheimer's disease across Europe

    Journal of Nutrition, Health and Aging, Vol. 14, Núm. 7, pp. 537-544

  2. Drug profile: Transdermal rivastigmine patch in the treatment of alzheimer disease

    CNS Neuroscience and Therapeutics, Vol. 16, Núm. 4, pp. 246-253

  3. Turning principles into practice in Alzheimer's disease

    International Journal of Clinical Practice, Vol. 64, Núm. 9, pp. 1198-1209